Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Bishop who wrote (17984)	12/27/1999 12:58:00 PM
From: SSP	Respond to of 150070

VGEN - Thus far, the Company's intention is to develop the following products designed to ameliorate sexual dysfunction: 1. An Intraureathral therapeutic treatment for male erectile dysfunction ("Male Intraureathral Product") 2. A topical therapeutic treatment for male erectile dysfunction ("Male Topical Product") 3. A topical therapeutic treatment for female sexual dysfunction ("Female Topical Product"), and 4. An orally administered form of liposomal, lyophilized Apomorphine for the treatment of male erectile dysfunction ("Male Oral Product") The Company is a development stage enterprise as defined by FASB No. 7. "Accounting and Reporting by Development Stage Enterprises".